This Is MS Multiple Sclerosis Community: Knowledge & Support

Positive interim results of two Phase I/II clinical trials for Tovaxin are released.
http://www.medicalnewstoday.com/medicalnews.php?newsid=25614

Hi, I am Tim,

Here is just a little of my story. So much has happened that I could write a book about my last two years. The vaccine appears to have arrested my disease and has done the same for the other people in the study.

I have two small websites that show a timeline of events. The first one ...

Keep in mind this is from an equity analyst, and they don't cite a source, but I like the sounds of the results of the FTY720 trials...


Biogen Idec's Avonex May Face 'Serious Pressure'

06.03.05 -- Morgan Stanley downgraded Biogen Idec to "equal-weight" from "overweight" and said the biotech firm's Avonex multiple sclerosis drug faces greater long-term risk than previously thought.

Recently released clinical data for FTY720, an experimental MS drug from Novartis (nyse: NVS ...

The results are good, but the number of patients assessed in this report is tiny! Oh well, they say they are planning to go to Phase II/III in late 2005 or early 2006!


PharmaFrontiers Announces Positive Interim Results of Two Phase I/II Clinical Trials for Multiple Sclerosis

June 3, 2005 -- BUSINESS WIRE -- PharmaFrontiers, a company involved in the development and commercialization of cell therapies, announced that interim results of Tovaxin(TM) in two Multiple ...

Interesting article I found on the web


Focis 2005 presentation: XIAP, a novel target in multiple sclerosis
Monday May 16, 9:01 am ET


MONTREAL, May 16 /PRNewswire/ - Aegera Therapeutics Inc. is pleased to announce the presentation of results of a study entitled "Apoptosis Induction as a Therapeutic Intervention to Eliminate Encepalitogenic T cells; Antisense XIAP (AEG35169) in Murine Models of EAE". The study and results were presented at the 5th Annual Meeting of the ...

anyone discuss this with their Doc. does it look like this will be on the market soon??

OK, techinically this trial is for ulcerative colitis, but they mention that their pre-clinical work suggested a number of potential targets for this drug, including MS...plus it's a monoclonal antibody and those are attracting a lot of attention these days, so I thought it was worth posting.


Medarex Announces Phase I Clinical Trial of MDX-1100, a Fully Human Anti-IP10 Antibody, for the Treatment of Ulcerative Colitis

May 11, 2005 - PRNewswire-FirstCall - Medarex, Inc. today ...

Dear all,

The Boston Cure Project site has posted an article today about Tovaxin - a T Cell vaccine. An individual provides details of his success with this treatment. Does anyone have any more information on this treatment - looks promising?

Bromley


http://www.bostoncure.org:8080/article. ... ode=nested


It's interesting how those treatments which stop attacks (Campath and Tovaxin), rather than just reduce attacks (the CRAB drugs only reduce the attacks by ...

Hi all

A Phase II Study of Atorvastatin (aka Lipitor) is now recruiting people across the US who have been diagnosed with Clinically Isolated Syndrome (CIS) and are at Risk for Multiple Sclerosis.

The definition of CIS, eligibility criteria and locations of centers recruiting people may be found here.

The study hypothesis states:

Early intervention with atorvastatin in patients with CIS will result in a state of immunological tolerance.

The eventual findings should be ...

Found this on the internet.

OxyPharma Announces Selection of Multiple Sclerosis (MS) Drug Development Candidate

STOCKHOLM, Sweden, April 5, 2005--Swedish drug development company OxyPharma has selected a candidate drug (CD) for the treatment of multiple sclerosis (MS) from its autoimmune diseases drug discovery program. The selected compound, Rob 895, is now ready to go into a full-scale pre-clinical program.

Rob 895 has been developed from OxyPharma's patented lead compound B-220, from which OxyPharma has developed ...

It's only completed phase I so far...


4SC SUCCESSFULLY CONCLUDES PHASE I STUDY FOR PRODUCT CANDIDATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES

24 March 2005 - 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have successfully concluded phase I studies for the small molecule product candidate SC12267 for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
A safe and well ...